Truist analyst Richard Newitter lowered the firm’s price target on Inari Medical to $65 from $70 and keeps a Buy rating on the shares. Intra-quarter data points, including the firm’s Q2 hospital survey, increase confidence that procedure momentum will extend beyond Q2 into 2H23 with MedTech companies poised to deliver healthy beat and raises, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NARI:
- Inari Medical initiated with an Outperform, $79 price target at Baird
- Inari Medical initiated with an Outperform at Baird
- Inari Medical to Announce Second Quarter 2023 Financial Results
- Penumbra price target raised to $376 from $325 at Deutsche Bank
- Inari Medical Announces the Release of 2022 Ethos and Sustainability Report